Clinical Research Directory

Inclusion Criteria: * Residents of Australia, Malaysia, Colombia, Kenya. * Have experienced acute primary headaches that occur 1 to 14 days a month on average in the past 1 month. * Have taken Panadol/Dolex for at least 1 headache episode in the past 1 month. * Self-reported healthy individuals. * Able to provide informed consent. * The specific Panadol/Dolex variant for each country as applicable. Exclusion Criteria: * Participants who experience headaches that occur 15 or more days per month. * Participants with migraine. * Participants who use any headache medication, pain relief product or alternative remedy (herbal products, supplements, CBD \[cannabidiol\]- containing pain remedies) concurrently with Panadol/Dolex for the recalled headache episode in the past 1 month. * Participants diagnosed by a healthcare professional with chronic pain conditions (fibromyalgia, neuropathic pain, cancer, lupus, multiple sclerosis) who were experiencing symptoms or receiving treatment for the condition at the time of reference headache episode when Panadol/Dolex was used. * Breastfeeding or Pregnant at the time of reference headache episode during which Panadol/Dolex was used. * Participants affiliated with Sponsor or Contract Research Organization (CRO).